News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
News Sanofi cuts price of Lantus insulin in US by 78% Pharma joins Eli Lilly, Novo Nordisk as it slashes the price of its widely-prescribed insulins.
News Novo Nordisk shadows Lilly with insulin price cut plan Danish drugmaker says it will reduce the price of its insulin products in the US by up to 75%.
News Sanofi buys Provention and diabetes drug Tzield for $2.9bn T1D prevention drug has been tipped as a blockbuster, boosting Sanofi's diabetes franchise.
News Sanofi boosts ‘connected insulin’ push with Glooko deal The alliance will pair Glooko's digital health platform with Sanofi's SoloSmart insulin device.
News Lilly injects $450m into plant making Mounjaro Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina t
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
